Anandamide (arachidonoylethanolamide, AEA) 1 belongs to an emerging class of endogenous lipids including amides and esters of long chain polyunsaturated fatty acids and is collectively termed "endocannabinoids" (1, 2) . In fact, AEA has been isolated and characterized as an endogenous ligand for both CB 1 and, to a lesser extent, CB 2 cannabinoid receptor subtypes, and has been shown to mimic the psychotropic, antiemetic, and analgesic effects of cannabinoids (3) . Recently, attention has been focused on the cardiovascular actions of AEA and their potential role in human shock conditions (4) . In particular, a role for AEA has been proposed in both endothelium-dependent and -independent relaxations of vascular tissues, which involve several mechanisms including hyperpolarization of the smooth muscle cell membrane (5) (6) (7) . A similar mechanism has been attributed in the past to a diffusible endothelium-derived hyperpolarizing factor (EDHF) different from nitric oxide (NO), whose chemical nature is still a matter of speculation (8) . In fact, AEA has been proposed as an EDHF (5), though this hypothesis is still under debate (9, 10) , and recent data strongly support the theory that EDHF is a cytochrome P450 metabolite (11) . Whether or not an EDHF, AEA is likely to play an important role in the control of vascular tone (for reviews see Refs. 4 and 12), as suggested also by the observation that both endothelial cells and macrophages release this as well as the other endocannabinoid, 2-arachidonoyl-glycerol (2-AG) (1, (13) (14) (15) (16) .
The pharmacological effects of AEA on CB 1 and CB 2 receptors depend, as for any other extracellular transmitter, on its life span in the extracellular space, which is limited by a two-step process: (i) its rapid and selective uptake by cells through the action of a membrane transporter and (ii) intracellular degradation. In particular, AEA is hydrolyzed to ethanolamine and arachidonic acid by the enzyme fatty acid amide hydrolase (FAAH) (17, 18) . Both components of this inactivation process of AEA are the objects of active investigations. Recent data seem to indicate that the uptake process is the rate-limiting step in AEA degradation (19 -23) . There is pharmacological evidence suggesting that also the hypotensive action of AEA in vivo is limited by its re-uptake (24) . However, the existence of the AEA membrane transporter in endothelial cells has never been investigated.
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cannabinoid receptors leads to NO release (13, 27, 28) , whereas AEA uptake is enhanced by NO donors (22) .
The results reported here demonstrate a saturable and temperature-dependent transport of AEA into endothelial cells. AEA uptake by human umbelical vein endothelial cells (HUVECs) is enhanced by various NO donors and further potentiated by superoxide anions. Conversely, a major cellular antioxidant and NO scavenger, glutathione, reduces the NO effect on the AEA transport. The observation that exogenously added NO donors may link CB receptors and HUVEC AEA transporter, through a CB receptor-mediated up-regulation of inducible NO synthase (NOS) and intracellular release of nitric oxide, appears to be the main outcome of this investigation. (21) . Linvanil (␣-linolenoyl-vanillyl-amide) was synthesized as reported (29) . HU-210 was kindly donated by Prof. R. Mechoulam (The Hebrew University of Jerusalem). Monoclonal antibodies against the inducible nitric oxide synthase (iNOS) were purchased from Transduction Laboratories. Rabbit polyclonal antibodies against the N-terminal region of the human CB 1 receptor were from Calbiochem, and rabbit polyclonal antibodies against the human apoptosis protease-activating factor 1 were purchased from Cayman Chemical. Goat anti-mouse antibodies conjugated with alkaline phosphatase were from Bio-Rad. Generation of superoxide anions (O 2 Ϫ ) was achieved by adding to the culture medium 100 M xanthine and 5 milliunit/ml xanthine oxidase (Sigma), which produces about 2 M O 2 Ϫ /min (30) . Endothelial Cell Culture-HUVECs were purchased from BioWhittaker and were cultured in 75-cm 2 flasks at a density of 2500/cm 2 in EGM-2 Bulletkit medium (BioWhittaker). HUVECs were maintained at 37°C in humidified 5% CO 2 atmosphere and were split every second day (at 70 -80% confluency) with daily replacement of the culture medium.
EXPERIMENTAL PROCEDURES

Materials-Chemicals
Determination of Anandamide Uptake-The uptake of [ 3 H]AEA by intact HUVECs was studied essentially as described (22) . Cells at the fourth to fifth passage were washed in phosphate-buffered saline, trypsinized with trypsin-EDTA (Life Technologies, Inc.), and resuspended in their serum-free culture media at a density of 1 ϫ 10 6 cells/ml. Cell suspensions (1 ml/test) were incubated for different time intervals, at 37°C, with 100 nM [ 3 H]AEA, and they were washed three times in 2 ml of culture medium containing 1% bovine serum albumin and were finally resuspended in 200 l of phosphate-buffered saline. Membrane lipids were then extracted (31) , resuspended in 0.5 ml of methanol, and mixed with 3.5 ml of Sigma-Fluor liquid scintillation mixture for nonaqueous samples (Sigma), and radioactivity was measured in a LKB1214 Rackbeta scintillation counter (Amersham Pharmacia Biotech). To discern noncarrier-mediated from carrier-mediated transport of AEA into cell membranes, control experiments were carried out at 4°C (22) . Incubations (15 min) were also carried out with different concentrations of [ 3 H]AEA, in the range 0 -1000 nM, to determine apparent K m and V max of the uptake by Lineweaver-Burk analysis (in this case, the uptake at 4°C was subtracted from that at 37°C). Q 10 value was calculated as the ratio of AEA uptake at 30 and 20°C (19) . AEA uptake was expressed as pmol of AEA taken up/min/mg of protein.
The effect of different compounds on AEA uptake (15 min) was determined by adding each substance directly to the incubation medium at the indicated concentrations. In the case of BSO or NAC, cells were preincubated for 6 h before assaying AEA uptake. Cell viability after each treatment was checked with Trypan blue and was found to be higher than 90% in all cases. Uptake of [ 3 H]2-AG by HUVECs was determined as reported previously for other cell types (16, 32 (34) . FAAH and NOS activities were expressed as pmol arachidonate or pmol citrulline released/min/mg of protein, respectively. The effect of various compounds on FAAH or NOS activity was determined by adding each substance directly to the assay buffer, at the indicated concentrations, and incubating for 15 min at 37°C. The expression of the iNOS at the protein level was determined by enzyme-linked immunosorbent assay, performed by coating the plate with cell homogenates (25 g/ well), prepared as described (34) . Anti-iNOS monoclonal antibodies (diluted 1:400) were used as first antibody, and goat anti-mouse antibodies conjugated with alkaline phosphatase were used as second antibody, diluted 1:2000. Color development of the alkaline phosphatase reaction was followed at 405 nm, using p-nitrophenylphosphate as substrate (34) . Controls included wells coated with different amounts of bovine serum albumin.
Determination of Glutathione Content in Endothelial Cells-The colorimetric assay based on 5,5Ј-dithiobis-(2-nitrobenzoic acid) was used to quantify glutathione, the only detectable thiol in endothelial cells (35) . HUVECs (2.5 ϫ 10 6 cells/test) were treated with different compounds (or vehicle alone in the controls) for 15 min, and they were washed in phosphate-buffered saline and centrifuged at 800 ϫ g, and pellets were resuspended in 75 l of trichloroacetic acid (5% in 0.1 M HCl, 10 mM EDTA). Supernatants from the 10,000 ϫ g centrifugation were recovered and aliquots of 60 l were mixed with 130 l of stock buffer (125 mM Na 2 PO 4 , 6.3 mM EDTA, pH 7.4). Ten l of stock buffer containing 6 mM 5,5Ј-dithiobis-(2-nitrobenzoic acid) were added to each sample, and after 30 min at room temperature in the dark the absorbance was read in a microtiter plate at 412 nm (extinction coefficient was 14.3 mM
) (35) . The glutathione content of cellular extracts was within the linearity range of the assay procedure, as assessed by calibration curves made with glutathione (Sigma). The sensitivity of the colorimetric assay was ascertained by incubating HUVECs for 6 h with 1 mM BSO or NAC, a selective inhibitor or a precursor of glutathione biosynthesis, respectively (35) .
Nitrite Production Assay-Generation of NO was determined by measuring accumulation of the stable end product nitrite (NO 2 Ϫ ) in culture supernatants (30, 36) . HUVECs (5 ϫ 10 6 cells/test) were treated with different compounds (or vehicle alone in the controls) for 15 min, and the nitrite levels were determined in the culture medium via spectrophotometric analysis, after using nitrate reductase (Alexis Corporation, LÄ ufelfingen, Switzerland) and the acid-catalyzed diazotation reaction with sulfanylamide and naphtylethylenediamine (Griess reaction) as described (35) . Nitrite levels in culture supernatants were within the linearity range of calibration curves made from a solution of sodium nitrite.
Determination of cAMP Concentration-HUVECs (5 ϫ 10 6 cells/test) were treated with different compounds (or vehicle alone in the controls) for 15 min, then medium was discarded, and the cells were trypsinized as described above. Cyclic AMP levels in acetylated HUVEC extracts were determined by the Cayman Chemical cAMP Enzyme Immunoassay kit (Alexis Corporation, Lä ufelfingen, Switzerland). Cyclic AMP in cellular extracts was within the linearity range of the method, calibrated with acetylated cAMP as suggested by the manufacturer.
Data Analysis-Data reported in this paper are the mean Ϯ S.D. of at least three independent experiments, each performed in duplicate. Statistical analysis was performed by the Student's t test elaborating experimental data by means of the InStat program (GraphPAD Software for Science).
RESULTS
Characterization of AEA Uptake by Endothelial Cells and Its
Modulation by NO-HUVECs were able to accumulate [ 3 H]AEA, a process which was temperature-(Q 10 ϭ 1.6), time-(t 1/2 ϭ 4 min) and concentration-dependent (Fig. 1A and 3 H]arachidonic acid and glycerol (see below) or directly inserted into membrane phospholipids in a temperature-dependent fashion (data not shown), as previously reported for J774 macrophages and rat basophilic leukemia (RBL-2H3) cells (16, 32) .
AEA uptake was dose dependently enhanced by the NO donors SNP, SNAP, or SPER-NO (Fig. 1B) , which led to a 2.2-fold increase when used between 2.5 mM (SNAP) and 5 mM (SNP or SPER-NO). The NO scavenger hydroxocobalamin (1 mM) abolished the stimulation of AEA uptake by 5 mM SNP or 2.5 mM SNAP. NO can readily react with O 2 Ϫ generating peroxynitrite (ONOO Ϫ ), a potent oxidant and nitrosylating agent (30) . Co-incubation of SNP or SNAP with a superoxide (O 2 Ϫ ) generating system, such as xanthine-xanthine oxidase (see "Experimental Procedures"), led to a further enhancement of AEA transport compared with NO donors alone, i.e. up to 2.7-and 3.2-fold the control compared with 2.0-and 2.5-fold with SNP or SNAP, respectively ( Fig. 2A) . Superoxide ions alone hardly affected AEA uptake (not shown). To test the hypothesis that peroxynitrite was more efficient than NO as a stimulator of AEA transport, SIN-1, which generates ONOO Ϫ via simultaneous release of NO and O 2 Ϫ in stoichiometric amounts (37), was used. SIN-1 (1 mM) was twice as effective as SNP (5 mM) or SNAP (2.5 mM) in enhancing AEA uptake by HUVECs, leading to a 4-fold increase over the untreated control ( Fig. 2A) . When peroxynitrite was added directly to the medium, a dose-dependent increase in AEA uptake by HUVECs was also observed. The transport increased from 18.5 Ϯ 1.2 to 32.3 Ϯ 2.5 or 39.4 Ϯ 3.4 pmol⅐min Ϫ1 ⅐mg Ϫ1 protein, in the presence of 150 or 300 M ONOO Ϫ , respectively. The presence of SOD (100 units/ml) in the medium significantly reduced the effect of SNP or SNAP on AEA transport into the endothelial cells (Fig. 2A) . The effect of SOD on AEA transport was more pronounced when the experiments were carried out with SIN-1 (from 4-to 1.5-fold of the control). Finally, the presence of O 2 Ϫ in excess over NO, as in the case of co-incubation of HUVECs with O 2 Ϫ and SIN-1, did not further potentiate AEA uptake by endothelial cells, which was instead slightly reduced ( Fig. 2A) .
Modulation of AEA Uptake by Glutathione-To examine whether intracellular glutathione could affect the activation of AEA uptake by NO donors, HUVECs were treated with NAC or BSO, a precursor or a selective inhibitor of glutathione biosynthesis, respectively (35) . NAC produced a 1.8-fold increase in intracellular glutathione (Fig. 3A) . Under these conditions, the induction of AEA transport by SNP, SNAP, or SIN-1 was markedly attenuated (Fig. 2B) . On the other hand, treatment with BSO reduced by 50% the glutathione content in HUVECs (Fig.  3A) , further enhancing the AEA uptake by any of the NO donors used (Fig. 2B) . It is worth noting that recently it has been shown that NO donors per se do not affect the intracellular glutathione concentration in endothelial cells (35) . signaling pathways (3, 39) . AEA (1 M) significantly decreased forskolin-induced cAMP in endothelial cells, and this effect was reversed by 0.1 M SR141716 but not SR144528. The potent CB 1 agonist HU-210 (1 M) (1) also reduced cAMP content in endothelial cells (Fig. 3B ). More importantly, this effect of AEA was potentiated by 10 M linvanil and canceled by 1 mM SIN-1 (Fig. 3B) , which inhibits or stimulates AEA transport, respectively. The other AEA transport inhibitor, AM404 (10 M), also enhanced AEA inhibition of cAMP levels (45 Ϯ 5% of control).
AEA Enzymatic Hydrolysis in Endothelial Cells
We found that AEA increased nitrite release from HUVECs in a dose-dependent manner (not shown), to ϳ2.6-fold above the controls at 1 M AEA. The CB 1 antagonist SR141716 (0.1 M), but not the CB 2 antagonist SR144528 (0.1 M), fully reversed the effect of AEA, whereas the agonist HU-210 (1 M) also led to a remarkable increase in nitrite release (Fig. 3C) . The NOS inhibitor L-NAME (13, 34) fully reverted the AEAinduced nitrite release when used at 400 M. A similar inhibitory effect was observed adding the protein synthesis inhibitor cycloheximide, but not the transcription inhibitor actinomycin D, both used at 10 g/ml. Interestingly, inhibition of the AEA transporter by either 10 M linvanil or 10 M AM404 enhanced AEA-induced NO release up to 3.9-and 3.7-fold over the untreated control, respectively (Fig. 3C and data not shown) . In keeping with these observations, exposure of HUVECs to 1 M AEA or HU-210 significantly increased NOS activity (up to 250% over the untreated control), an effect which was blocked by 0.1 M SR141716, but not 0.1 M SR144528, and, in the case of AEA, again enhanced by 10 M linvanil (325% of the control) (Table II) . Changes in NOS activity were always paralleled by changes of (inducible) NOS protein content (Table II) . Thus, 10 M AM404 potentiated the effect of AEA on both NOS activity (310 Ϯ 31% of the control) and content (270 Ϯ 27% of the control) in a way superimposable to that observed with 10 M linvanil (Fig. 3, B and C, and Table II) . Conversely, activation of the AEA transporter by 1 mM SIN-1 inhibited AEA-induced NOS activity and content (Table II) . Finally, AEA alone or in the presence of SR141716, SR144528, linvanil, or AM404 was always unable to modulate the intracellular glutathione concentration, as was HU-210 (Fig. 3A) .
To check a possible NO-mediated functional link between the CB 1 receptor and the AEA transporter, the effect of HU-210 on AEA uptake was measured. HU-210 dose dependently enhanced AEA accumulation into cells, up to about 2.2-fold over the untreated control in the presence of 1 M of the agonist (Table I ). The CB 1 antagonist SR141716 (0.1 M) counteracted the effect of 1 M HU-210, whereas the CB 2 antagonist SR144528 was ineffective at the same concentration (Table I) . Moreover, rabbit anti-human CB1 receptor antibodies (in the range 0 -15 g/ml or 0 -0.1 M) counteracted the effect of 1 M HU-210 on AEA uptake in a dose-dependent manner; at 0.1 M these antibodies significantly (p Ͻ 0.05) reduced AEA uptake by HUVECs from 216 to 150% of the untreated control. Rabbit anti-human apoptosis protease-activating factor 1 antibodies were ineffective under the same experimental conditions. Finally, the NOS inhibitor L-NAME also blocked HU-210-induced enhancement of AEA uptake (Table I) . DISCUSSION We have shown that HUVECs have the ability to rapidly take up AEA in a temperature-dependent and saturable way. The AEA transporter in HUVECs exhibited a maximum velocity (apparent V max ϭ 45 Ϯ 3 pmol⅐min Ϫ1 ⅐mg Ϫ1 protein) closer to that reported for human neuroblastoma CHP100 cells (30 Ϯ 3 pmol⅐min Ϫ1 ⅐mg Ϫ1 protein) than that reported for human lymphoma U937 cells (140 Ϯ 15 pmol⅐min Ϫ1 ⅐mg Ϫ1 protein) (22) . As previously shown in murine central neurons (17) and leukocytes (14) , as well as in human neuroblastoma and lymphoma cells (22) , the facilitated uptake process in HUVECs is likely to be followed by AEA hydrolysis catalyzed by FAAH (18) . In fact, FAAH in HUVECs had kinetic properties similar to the hydrolase in CHP100 cells (22) . The somewhat lower V max value for FAAH toward AEA (25 Ϯ 3 pmol⅐min Ϫ1 ⅐mg Ϫ1 protein) should not forbid an efficient hydrolysis of AEA by endothelial cells, because the uptake rate into cells was similar. Moreover, we cannot rule out the possibility that other AEA-hydrolyzing activities with a different optimal pH, such as the enzyme recently described by Ueda's group (40) , are present in endothelial cells besides FAAH. Interestingly, the HUVEC AEA transporter could be inhibited not only by the previously reported inhibitor of AEA-facilitated transport, AM404 (20) , but also by a long chain fatty acid capsaicin analogue, linvanil, previously shown to inhibit the RBL-2H3 cell AEA transporter (29) . This compound was selected for this study instead of other capsaicin analogues, such as olvanil and arvanil (29, 41, 42) , because it exhibits very low affinity for cannabinoid receptors (29) .
2-AG is another putative endogenous ligand for cannabinoid receptors (1, 15) . This compound is produced and released by HUVECs on stimulation with the calcium ionophore A23187 or thrombin (15) and biosynthesized by aortic endothelial cells after treatment with carbachol (43). 2-AG was also shown to be produced and inactivated by rat platelets and macrophages (16) . Because this compound also exerts a vasodilatory action (43, 44), we investigated 2-AG uptake by endothelial cells. Although we observed that 2-AG competitively inhibited AEA uptake, we did not get evidence for its temperature-dependent accumulation into intact HUVECs, possibly because this process may have been obscured or made unnecessary by the rapid esterification into membrane phospholipids and/or hydrolysis of 2-AG that were observed here as well as in other cell systems (16, 32) .
NO donors SNP, SNAP, and SPER-NO are chemically unrelated compounds, which at millimolar concentrations release nanomolar concentrations of NO in solution (45, 46) . We have previously shown that NO donors can enhance the activity of the AEA transporter in human neuroblastoma cells and platelets (22, 47) . Accordingly, in HUVECs we found that NO donors activate the AEA transporter in a way proportional to their ability to release NO (48), 2.5 mM SNAP being approximately as effective as 5 mM SNP or SPER-NO (Fig. 1B) . Therefore, 2.5 mM SNAP or 5 mM SPER-NO were chosen to further characterize the sensitivity of AEA uptake to NO. Interestingly, superoxide anions and intracellular glutathione modulate the stimulation of AEA transporter by NO donors in cultured endothelial cells (Fig. 2) . Superoxide anions (O 2 Ϫ ) enhanced the effect of SNP or SNAP on AEA uptake, whereas SOD significantly reduced the effect of both NO donors (Fig. 2A) . Because NO rapidly reacts with O 2 Ϫ to give peroxynitrite (ONOO Ϫ ), we investigated the possibility that ONOO Ϫ might activate AEA transporter better than NO. To this end, SIN-1, which generates ONOO Ϫ via simultaneous release of NO and O 2 Ϫ in stoichiometric amounts (37) , was used and was found to be more effective than SNP or SNAP (Fig. 2A) . Also, peroxynitrite directly added to the incubation medium led to a concentrationdependent increase in AEA uptake. It should be stressed that ONOO Ϫ may contribute to S-nitrosylation of target proteins in vivo better than NO does (30) . Moreover, it has been proposed that NO synthase activity favors the formation of ONOO Ϫ rather than that of NO (49) . In this context, it seems noteworthy that generation of O 2 Ϫ in excess over NO, as in the case of co-incubation of HUVECs with O 2 Ϫ and SIN-1, failed to potentiate the effect of SIN-1 on AEA uptake, which was instead slightly reduced ( Fig. 2A) . Indeed, excess superoxide anions have been shown to inhibit the nitrosylation reaction in vitro (30) . Taken together, our results suggest a possible involvement of ONOO Ϫ in enhancing AEA uptake in vivo and indicate that this effect can be attenuated by preventing the direct interaction between NO and O 2 Ϫ through scavengers of these two radical molecules. Consistent with this hypothesis, depletion or enhancement of intracellular glutathione concentration potentiated or attenuated, respectively, the effect of NO donors on AEA transport into HUVECs (Fig. 2B) . Indeed, although it is commonly accepted that NO diffuses freely in tissues, a recent report considers that, to reach its targets, NO needs to diffuse through the intracellular environment where glutathione levels are in the millimolar range (50) . Glutathione is the most important cellular nonprotein thiol and constitutes the major cellular antioxidant (35) . Moreover, glutathione binds to NO and forms S-nitrosoglutathione, a long lived NO derivative found in a variety of organ systems and biological fluids (51) . In blood, nitrosoglutathione participates with S-nitroso serum albumin and S-nitroso hemoglobin in controlling transport, delivery, and disposal of nitric oxide (52, 53) . Our data strongly suggest that, under certain conditions, glutathione may prevent NO from activating the AEA transporter.
A previous pharmacological study (24) had suggested that termination of the hypotensive effect of AEA in vivo could be effected through a re-uptake process. In this study we have provided biochemical evidence to this observation by showing that the AEA transporter regulates the activity of AEA in living endothelial cells. In fact, inhibition of AEA uptake by the selective AEA transport inhibitors, linvanil and AM404, or its activation by the peroxynitrite donor, SIN-1, enhance or inhibit, respectively, AEA effects on both forskolin-induced adenylyl cyclase and NO synthesis (Table II and Fig. 3) . However, when another AEA effect, i.e. endothelium-dependent vasodilation, is monitored instead, inhibition of the transporter may also result in the reduction of AEA activity (54), possibly because this action requires the interaction of the endocannabinoid with an intracellular target.
Given their sensitivity to the selective CB 1 antagonist SR141716, the effects of AEA and HU-210 on NO release and forskolin-induced cAMP formation are likely to be mediated by activation of CB 1 -like receptors, whose presence in HUVECs had been suggested by Sugiura's group (15) by using reverse transcriptase-polymerase chain reaction. Additionally, a recent study suggested the presence, in endothelial cells, of an SR141716-sensitive, non-CB 1 -non-CB 2 site of action for AEA and the nonpsychotropic cannabinoid, abnormal cannabidiol (55) . Although more potent than AEA on CB 1 , HU-210 does not activate this new site of action. This may explain why, in HUVECs, the synthetic cannabinoid appeared to be as efficacious as AEA (Fig. 3) . However, only a full dose-response evaluation of the effects of both AEA and HU-210 on cAMP and NO levels in HUVECs would establish which of the two compounds is more potent in these cells.
Whereas the inhibition of forskolin-induced cAMP formation in endothelial cells by AEA was never reported before, previous studies (13, 27, 28) have shown that the endocannabinoid can induce NO release in these cells by acting at CB 1 -like receptors. This effect was because of the activation of endothelial (constitutive) NOS and possibly resulted in the inhibition of cAMP formation (27) . However, the present report is the first showing that AEA can cause NO release also by stimulating the activity and expression of the endothelial-inducible NOS isoform. In fact, AEA-induced NO release was not only reduced by the NOS inhibitor L-NAME but even required protein, but not messenger RNA, synthesis, as demonstrated by the experiments with cycloheximide and actinomycin D (Fig. 3C) . NOS activity was paralleled by iNOS expression in the same cells (Table II) showing that the inducible form of NOS was part of the signaling pathway initiated by the CB 1 receptor. This finding extends previous observations showing that iNOS in HUVECs is rapidly modulated by growth factors, vasoactive hormones and estrogens (56 -58) . However, we could not establish to what extent the NO release was because of activation of either of the two NOS isoforms.
We suggest that NO donors might play a physiological regulation of AEA uptake, possibly linked to the activation of CB1 receptors by AEA. In fact, we found that the selective cannabinoid receptor agonist HU-210, while inducing NO release from HUVECs, significantly enhances [ 3 H]AEA uptake in a process sensitive to the NOS inhibitor L-NAME (Table I) . Apart from a low concentration of the CB 1 receptor antagonist SR141716, this effect was also reduced by co-incubation with a polyclonal antibody against the extracellular domain of CB 1 , thus pointing to the possible functional link between activation of cannabinoid receptors and withdrawal of AEA by the selective transporter identified in this study. According to this model depicted in Scheme I, AEA binding to cannabinoid receptors enhances the expression and the activity of NOS, which generates NO. The latter mediator then activates the AEA transporter even more in the presence of superoxide anions, whereas glutathione reduces the effect of NO by entrapping it into S-nitrosoglutathione. Once taken up by endothelial cells, AEA can be degraded by FAAH to arachidonic acid and ethanolamine. This scheme may represent a new, interesting mechanism through which AEA can limit its own CB 1 -mediated actions. Indeed, preliminary experiments carried out in our laboratory 2 show that the endocannabinoid is toxic to some non-CB 1 -containing tumor cells, probably also because they may be less efficient in the disposal of AEA through enhanced uptake.
The dependence of AEA transport into cells on NO/O 2 Ϫ formation might also represent an oxidative stress-induced mechanism for the reduction of extracellular AEA levels, while an increase of the anti-oxidative defense, through N-acetylcys-teine and glutathione, would prevent the stress response by inhibiting ONOO Ϫ -induced AEA uptake thus leading to an enhancement of AEA concentration. This hypothesis is in agreement with a cell-protecting role of AEA, for example during ischemic conditions (for reviews see Refs. 4 and 59).
Finally, it seems noteworthy that scheme I (with NO release promoting the termination of AEA signaling) establishes an inverse relationship between nitric oxide and anandamide, two relaxing factors derived both, at least in part, from endothelial cells. This type of relationship between endothelial-derived relaxing substances is not unprecedented in the literature as NO was shown to inhibit the release of the as yet uncharacterized EDHF (60), whereas activation of endothelial CB 1 receptors was recently reported to be negatively coupled to the production of EDHF (10) . Although the physiological and pathological significance of these compensatory mechanisms remains to be established, our findings demonstrate that the potency and duration of AEA action in living cells are modulated by physiopathological stimuli coupled to NO release.
